Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have earned an average rating of “Moderate Buy” from the fifteen research firms that are currently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $24.10.

A number of research analysts have recently weighed in on the stock. Guggenheim initiated coverage on shares of Kura Oncology in a report on Thursday. They set a “neutral” rating on the stock. Mizuho cut their target price on Kura Oncology from $32.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, May 19th. JMP Securities reduced their price target on Kura Oncology from $28.00 to $24.00 and set a “market outperform” rating for the company in a research report on Monday, August 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 26th. Finally, Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a research note on Friday, June 20th.

Kura Oncology Stock Up 1.1%

Shares of Kura Oncology stock opened at $8.22 on Friday. The firm has a market cap of $713.50 million, a price-to-earnings ratio of -3.64 and a beta of 0.19. The stock has a 50-day simple moving average of $6.66 and a 200-day simple moving average of $6.58. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $21.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.16 and a quick ratio of 6.16.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.90). The company had revenue of $15.29 million for the quarter, compared to analysts’ expectations of $64.95 million. On average, equities research analysts expect that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Institutional Trading of Kura Oncology

A number of institutional investors and hedge funds have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Kura Oncology during the 1st quarter worth $139,000. Rhumbline Advisers lifted its position in Kura Oncology by 5.2% during the 1st quarter. Rhumbline Advisers now owns 105,206 shares of the company’s stock worth $694,000 after acquiring an additional 5,215 shares during the last quarter. Hsbc Holdings PLC boosted its holdings in Kura Oncology by 26.5% during the first quarter. Hsbc Holdings PLC now owns 54,491 shares of the company’s stock valued at $351,000 after acquiring an additional 11,406 shares during the period. BNP Paribas Financial Markets boosted its holdings in Kura Oncology by 969.9% during the fourth quarter. BNP Paribas Financial Markets now owns 163,559 shares of the company’s stock valued at $1,425,000 after acquiring an additional 148,272 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Kura Oncology by 7.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company’s stock valued at $1,147,000 after purchasing an additional 9,050 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.